Drugs / recombinant gp100 protein (184V)
recombinant gp100 protein (184V)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00072085 | Sep 2003 → Jul 2006 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant gp100 protein (184V) | “recombinant gp100 protein (184V) emulsified in Montanide ISA-51” NCT00072085 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00072085 ↗ |
| Modality | Protein / enzyme biologic | “two different gp100 protein vaccines” NCT00072085 ↗ |
| Route | Subcutaneous | “recombinant gp100 protein (184V) emulsified in Montanide ISA-51 subcutaneously (SC)” NCT00072085 ↗ |